Skip to main content
four illustrated demodex mites in front of an eye appear scared of liquid coming out of eye drop bottle

READY TO START ENDING YOUR MITE PARTY?

Here’s How to Get XDEMVY®

four illustrated demodex mites in front of an eye appear scared of liquid coming out of eye drop bottle

Images are character representations of Demodex mites.

Get the First and Only FDA-Approved  Treatment for Demodex Blepharitis (DB)

  • If you’re experiencing eyelid redness and crusties (collarettes), make an appointment to see an eye doctor and ask them to check for DB. Only an eye doctor can properly diagnose DB.1
  • If you are diagnosed with DB, ask your doctor about XDEMVY—the only FDA-approved treatment that targets and kills the Demodex mites that cause DB.2,3
  • Our Find a Doctor tool can help you locate an eye doctor in your area who is knowledgeable about Demodex blepharitis (DB). Schedule an appointment today to get your eyelids checked.
four illustrated demodex mites in front of an eye appear scared of liquid coming out of eye drop bottle

Images are character representations of Demodex mites.

two illustrated demodex mites are paralyzed one says uh oh in speech bubble with text reading party’s over
two illustrated demodex mites are paralyzed one says uh oh in speech bubble with text reading party’s over
References

References: 1. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 2. Data on File. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals, Inc. 3. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.

References: 1. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 2. Data on File. XDEMVY Pivotal Trial Data Presentation. Tarsus Pharmaceuticals, Inc. 3. XDEMVY [prescribing information]. Tarsus Pharmaceuticals, Inc; 2023.